DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus.

DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus.

GV-TH-01, a Phase 1 open-label trial of a DNA prime—Modified Vaccinia Ankara (MVA) boost vaccine (GOVX-B11), was undertaken in HIV infected participants on antiretroviral treatment (ART) to evaluate safety and vaccine-elicited T cell responses, and explore the ability of elicited CD8+ T cells to con...

Full description

Bibliographic Details
Main Authors: Melanie Thompson, Sonya L Heath, Bentley Sweeton, Kathy Williams, Pamela Cunningham, Brandon F Keele, Sharon Sen, Brent E Palmer, Nicolas Chomont, Yongxian Xu, Rahul Basu, Michael S Hellerstein, Suefen Kwa, Harriet L Robinson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5053438?pdf=render

Internet

http://europepmc.org/articles/PMC5053438?pdf=render

Similar Items